Rizhao Lanshan Biochemical Products Co.,Ltd.

Rizhao Lanshan Biochemical Products Co., Ltd. is a wholly foreign-owned enterprise established with investment from Swiss company IBSA. The company was founded in 2002 and currently has a net asset of 100 million yuan. The company achieved an annual sales revenue of 106.72 million yuan and a research and development investment of 5.52 million yuan in 2021. All company workshops are constructed in accordance with GMP standards. The company currently has 105 employees, of which more than 3% have a master's degree or above in research, over 65% have a college degree or above, and about 30% have intermediate or junior professional titles. Since its establishment, the company has successively won titles such as "Advanced Export Enterprise" and "Advanced Enterprise in Conservation and Intensive Land Use" at the provincial and municipal levels, and ranked second in the comprehensive evaluation of "yield per mu" in the province and city in 2019. The continuous improvement of production technology has enabled the company's two achievements, "chondroitin sulfate fermentation production process" and "research on separation and purification of high specific activity urinary follicle stimulating hormone", to be evaluated and identified, reaching the international advanced level, transforming static scientific research achievements into tangible productivity and becoming the driving force and vitality of economic development. In recent years, the company has obtained 4 invention patents and 9 effective utility models; In 2018, we successfully applied to become a "Shandong Province One Enterprise One Technology Center" and a "Provincial Enterprise Technology Center". In 2019, it became the Engineering Technology Research Center for Polysaccharide Drug Development in Rizhao City. Apply to become a "high-tech enterprise" at the end of 2019. Successfully applied to become a key laboratory in Rizhao City by the end of 2021. The company has obtained dual certification from both the European Union and domestic drug regulatory authorities: in August 2012, it obtained the 2010 version of the "Drug GMP Certificate" (certificate number SD20120041); In 2012, it successfully passed the ANSM certification in France and underwent another review in May 2015. In 2020, the company's laboratory successfully obtained CNAS accreditation.